Partner David Rosen was quoted in a Newsweek article published on May 1, 2014, titled “Be Still, My Bioficial Heart.” The article explained the benefits and challenges of creating a “bioficial heart,” which researchers at the University of Louisville recently announced could be developed using living cells from a potential transplant patient combined with artificial materials to create a fully functional 3-D printed heart. Given that the U.S. Food and Drug Administration (FDA) is many years out from approving lab-built organs for patients, Rosen said, “The potential challenges include demonstrating that the organs will function as predicted, demonstrating the sustainability of these organs once transplanted and obtaining approval to test and market these from [the] FDA.”
People
Related News
April 3, 2026
In the News
David Rosen Weighs in on FDA's Pharma PR Crackdown – 'Stick to the Data'
Foley & Lardner LLP partner David Rosen shared insights on the regulatory challenges pharmaceutical companies face when publicly communicating around new cancer therapies in the MM+M article, “When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio.”
April 2, 2026
In the News
Susan Poll Klaessy and Adrienne Walker Named Chair and Vice Chair of Foley’s Bankruptcy & Business Reorganizations Practice
Foley & Lardner LLP partner Susan Poll Klaessy was appointed chair of the firm’s global Bankruptcy & Business Reorganizations Practice Group. Partner Adrienne Walker will serve as vice chair, supporting the continued growth and strategic direction of the practice.
April 1, 2026
In the News
Foley Featured on Top 10 Sales of 2025 List by Golf Inc.
Foley & Lardner LLP advised on two transactions named among Golf Inc.’s Top 10 Sales of 2025.